Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 4Uterine Cervical Dysplasia 2Neoplasms 2Precancerous Conditions 1Papilloma 1Neoplasms, Squamous Cell 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1

Interventions

Carboplatin 4Sunitinib 3Rituximab 3Pemetrexed 3ponatinib 2pembrolizumab 2osimertinib 2Vincristine 2Prednisone 2Gemcitabine 2Etoposide 2Doxorubicin 2Cyclophosphamide 2ricolinostat 1pralsetinib 1pomalidomide 1nilotinib 1linifanib 1ibritumomab tiuxetan 1emvododstat 1atezolizumab 1Temozolomide 1Taxes 1Sorafenib 1Papanicolaou Test 1Paclitaxel 1Melphalan 1Irinotecan 1Interleukin-2 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms by Histologic Type × Colposcopy × Clear all
NCT01234480 2023-05-16

Intended Use Study of the BD SurePath Plusâ„¢ Pap

Becton, Dickinson and Company

Terminated
5,859 enrolled 4 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡